The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shavlovskaya O.A.

International University of Restorative Medicine, Moscow, Russia

The effectiveness of citicoline in the treatment of cognitive disorders

Authors:

Shavlovskaya O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(3): 136‑140

DOI: 10.17116/jnevro2026126031136

Read: 350 times

Buy for 300₽
Contact the author
Table of contents

THE EFFECTIVENESS OF CITICOLINE IN THE TREATMENT OF COGNITIVE DISORDERS
THE EFFECTIVENESS OF CITICOLINE IN THE TREATMENT OF COGNITIVE DISORDERS

To cite this article:

Shavlovskaya OA. The effectiveness of citicoline in the treatment of cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(3):136‑140. (In Russ.)
https://doi.org/10.17116/jnevro2026126031136

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
Primary progressive apha­sia in the neurologist practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):61-66
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
The possibility of using neurotropic therapy in patients with persistent postural-perceptual dizziness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):89-94
Contemporary aspe­cts of brain protection in aortic arch surgery. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):164-173
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Abstract:

Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4—12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3—9 months; 3) CI against the background of CCI at a dose of 500—2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson’s disease at a dose of 1000 mg/day 12—18 months.

Keywords:

cognitive disorders
post-stroke cognitive impairment
post-stroke cognitive impairment
cerebrovascular disease
stroke
citicoline
Recognan

Authors:

Shavlovskaya O.A.

International University of Restorative Medicine, Moscow, Russia

Received:

17.02.2026

Accepted:

02.03.2026

Close metadata

References:

  1. Tkacheva ON, Yakhno NN, Neznanov NG, et al. Clinical guidelines «Cognitive disorders in the elderly and senile persons». S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3-3):7-149. (In Russ.). https://doi.org/10.17116/jnevro2025125337
  2. Bermejo PE, Dorado R, Zea-Sevilla MA. Role of citicoline in patient with mild cognitive impairment. Neurosci Insights. 2023;18:26331055231152496. https://doi.org/10.1177/26331055231152496
  3. Secades JJ, Gareri P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(s05):S1-S89.  https://doi.org/10.33588/rn.75S05.2022311
  4. Kansakar U, Trimarco V, Mone P, et al. Choline supplements: An update. Front Endocrinol. 2023;14:1148166. https://doi.org/10.3389/fendo.2023.1148166
  5. Marti-Carvajal AJ, Valli C, Marti-Amarista CE, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev. 2020; 8(8):CD013066. https://doi.org/10.1002/14651858.CD013066.pub2
  6. Bonvicini M, Travaglini S, Lelli D, et al. Is citicoline effective in preventing and slowing down dementia? — A systematic review and a meta-analysis. Nutrients. 2023;15(2):386.  https://doi.org/10.3390/nu15020386
  7. Zhao X, Huo X, Meng Y, et al. The efficacy of different doses of citicoline in improving the prognosis of patients with acute ischemic stroke based on network meta-analysis. Front Pharmacol. 2025;16:1529647. https://doi.org/10.3389/fphar.2025.1529647
  8. Li M, Huo X, Chang Q, et al. Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis. Front Pharmacol. 2024;15:1475021. https://doi.org/10.3389/fphar.2024.1475021
  9. Alvarez-Sabín J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive. Cerebrovasc Dis. 2013; 35(2):146-154.  https://doi.org/10.1159/000346602
  10. Alvarez-Sabín J, Santamarina E, Maisterra O, et al. Long-term treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke. Int J Mol Sci. 2016;17(3):390.  https://doi.org/10.3390/ijms17030390
  11. Almera M, Alvarez I, Molina-Seguin J, et al. Citicoline may prevent cognitive decline in patient with cerebrovascular disease. Clin Interv Aging. 2023;18:1093-1102. https://doi.org/10.2147/CIA.S409994
  12. Li Y, Cui R, Liu S, et al. The efficacy and safety of post-stroke cognitive impairment therapies: an Umbrella review. Front Pharmacol. 2023;14:1207075. https://doi.org/10.3389/fphar.2023.1207075
  13. Fan X, Shen W, Wang L, Zhang Y. Efficacy and safety of DL-3-nbutylphthalide in the treatment of poststroke cognitive impairment: a systematic review and meta-analysis. Front Pharmacol. 2021;12:810297. https://doi.org/10.3389/fphar.2021.810297
  14. Wang Y, Li M, Jiang Y, Ji Q. Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis. Front Neurosci. 2025;18:1530987. https://doi.org/10.3389/fnins.2024.1530987
  15. Wu D, Pan J, Fang X, Chen Z. Comparison of the effects of citicoline and vascular rehabilitation capsules on neurotrophic and inflammatory factors in patients with cerebral infarction. J Med Biochem. 2025;44(4):724-730.  https://doi.org/10.5937/jomb0-55775
  16. Secades JJ, Trimmel H, Salazar B, González JA. Citicoline for the management of patients with traumatic brain injury in the acute phase: a systematic review and meta-analysis. Life. 2023;13:369.  https://doi.org/10.3390/life13020369
  17. Nakazaki E, Mah E, Sanoshy K, et al. Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. J Nutr. 2021;151(8):2153-2160. https://doi.org/10.1093/jn/nxab119
  18. Mangalagiu AG, Petrescu BM, Riga S, Vasiliu O. Mild cognitive impairment: from symptomatic treatment to disease modification — a narrative review. Pharm Man NeuroSci. 2026;7(1):2.  https://doi.org/10.3390/neurosci7010002
  19. Mashin VV, Belova LA, Bakhtogarimov IR, et al. Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(8):39-43. (In Russ.). https://doi.org/10.17116/jnevro20171178139-43
  20. Bogolepova AN, Burd SG, Lebedeva AV, Kovalenko EA. Experience with citicoline in patients with post-stroke cognitive impairment. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):43-48. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-43-48
  21. Shchepankevich LA, Gribacheva IA, Popova TF, et al. Clinical experience with the use of citicoline in mild cognitive impairment of vascular origin. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):74-79.  https://doi.org/10.14412/2074-2711-2023-4-74-79
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.